• PathvysionTM. In breast cancer, gene HER2/neu amplification and its detection through in situ fluorescent in paraffin cuts, has a big value as regarding the prognosis as its treatment. It is a test to detect, thanks to fluorescence (FISH), the number of copies of oncogen HER2/Neu and allows to establish precisely and objectively if it is amplified or not. Oncologists recognize that the information regarding amplification is essential for a better treatment and to predict patients’ survival. It is the only HER2 evaluation method approved by the American FDA for three suggestions: To establish the prognosis, specify the treatment with adriamycin and selection for Herceptin®, a monoclonal antibody.
This technique reduces the false positives and the false negatives associated with the immunohistochemical (IHQ), which is the conventional way of estimating the amplification of the gene. 16% of the negative IHQ (classified as 0/1+) are positive using the FISH. These false negatives deprive a patient of a beneficial therapy. On the contrary, a 40% of the positive IHQ (classified as 2+/3+) are negative using FISH, and these false positives involve an expensive treatment which, in addition, is not effective.
The American Society of Clinical Oncology recommends a Her2/Neu evaluation in all primary breast cancers, when diagnosed and when it is recurrent.
• UrovysionTM. The Medical Genetics Unit is provided with a specialized staff in all mentioned techniques and it is headed by a specialist in Medical Genetics, member of the American Society of Human Genetics (ASHG) and the American College of Medical Genetics (ACMG).
The fluorescent technique based on fluorescence probes for the chromosomes 3,7,9 and 17 for the diagnosis and follow up of urothelial recurrent cancer.
It is the first genetic diagnosis approved by the American FDA and with CE brand, as for diagnosis as for the urothelial cancer follow-up, especially the bladder one. It uses present cells in the samples of urine or of bladder washout, as in cytology.
Its usage is addressed to initial bladder cancer detection in patients with hematuria and eventual recurrences surveillance of this cancer. It can detect the appearance of a recurrence up to six months before it is clinically objective, helping thus to a better treatment for patients.
UrovysionTM has major sensibility than the cytology for cancer detection, independently of the stage and tumor grade and, at least, the same speciality. Moreover, the sensibility is greater in those tumors with major tendency to relapse, and its results are not affected by the BCG treatment. This is conceived to be used together with other diagnosis methods, and not instead of them, improving this way both the sensibility and the diagnosed specificity.
The Medical Genetics Unit is provided with a specialized staff in all mentioned techniques and it is headed by a specialist in Medical Genetics, member of the American Society of Human Genetics (ASHG) and the American College of Medical Genetics (ACMG).